Drug & intervention

doxorubicin hydrochloride

RxCUI 142433

Clinical trials121
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Doxorubicin

Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It is often used together with other chemotherapy agents. Doxorubicin is given by injection into a vein. Common side effects include hair loss, bone marrow suppression, vomiting, rash, and inflammation of the mouth. Other serious side effects may include allergic reactions such as anaphylaxis, heart damage, tissue damage at the site of injection, radiation recall, and treatment-related leukemia. People often experience red discoloration of the urine for a few days. Doxorubicin is in the anthracycline and antitumor antibiotic family of medications. It works in part by interfering with the function of DNA. Doxorubicin was approved for medical use in the United States in 1974. It is on the World Health Organization's List of Essential Medicines. Versions that are pegylated and in liposomes are also available; however, they are more expensive. Doxorubicin was originally made from the bacterium Streptomyces peucetius.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)NCT06797635 · 2025-03-20
RECRUITING
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast CancerNCT04081389 · 2019-12-06
COMPLETED
Breast Cancer Treatment Based on Organ-like CultureNCT03925233 · 2019-01-02
UNKNOWN
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerNCT02648477 · 2016-03-28
COMPLETED
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerNCT02488967 · 2015-07-26
ACTIVE_NOT_RECRUITING
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaNCT02306161 · 2014-12-12
ACTIVE_NOT_RECRUITING
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast CancerNCT01897441 · 2013-06-01
TERMINATED
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast CancerNCT01750073 · 2012-12-07
COMPLETED
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast CancerNCT01697293 · 2012-01-01
TERMINATED
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerNCT01275677 · 2011-02-08
COMPLETED
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing SurgeryNCT01147016 · 2010-07-01
TERMINATED
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer PatientsNCT01099436 · 2010-04-01
COMPLETED
S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast CancerNCT00856492 · 2010-04-01
COMPLETED
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryNCT00861705 · 2009-07-21
COMPLETED
Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast CancerNCT00994968 · 2009-07-01
UNKNOWN
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast CancerNCT00895414 · 2009-04-01
COMPLETED
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung CancerNCT00856037 · 2009-02-02
COMPLETED
Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by SurgeryNCT00801411 · 2008-10-01
UNKNOWN
Chemotherapeutic Agents in Brain/BreastNCT00795678 · 2008-09-01
COMPLETED
Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344NCT00897026 · 2008-07-01
COMPLETED
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and TrastuzumabNCT00875238 · 2008-06-01
COMPLETED
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast CancerNCT00679029 · 2008-05-02
TERMINATED
Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by SurgeryNCT00589238 · 2008-01-01
TERMINATED
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast CancerNCT00629278 · 2007-12-01
UNKNOWN
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast CancerNCT00433511 · 2007-11-02
ACTIVE_NOT_RECRUITING
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast CancerNCT00513695 · 2007-06-01
COMPLETED
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast CancerNCT00755313 · 2007-05-01
COMPLETED
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By SurgeryNCT00436566 · 2007-03-16
COMPLETED
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast CancerNCT00482391 · 2007-03-01
COMPLETED
Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast CancerNCT00516425 · 2007-01-01
UNKNOWN
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast CancerNCT00533936 · 2006-09-01
UNKNOWN
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast CancerNCT00436709 · 2006-07-01
UNKNOWN
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)NCT00499083 · 2006-05-01
COMPLETED
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With SurgeryNCT00407888 · 2006-05-01
COMPLETED
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast CancerNCT00310089 · 2006-01-01
COMPLETED
Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By SurgeryNCT00424203 · 2006-01-01
COMPLETED
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast CancerNCT00343863 · 2006-01-01
COMPLETED
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast CancerNCT00119262 · 2005-10-01
COMPLETED
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast CancerNCT00295893 · 2005-09-27
ACTIVE_NOT_RECRUITING
Docetaxel, Doxorubicin, and Prednisone in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone TherapyNCT00416533 · 2004-08-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.